Measles vaccine(BioNet-Asia Co. Ltd.)

Measles is a severe and infectious disease triggered by a virus. Early symptoms of the disease are fever, red eyes, runny nose, and cough. Later, red spots and tiny rashes are observed on skin. Measles is spread by a virus belonging to the paramyxovirus family, genus Morbillivirus. The diameter of virus is 120 nm to 250 nm. Measles only occurs in humans and not in animals. The measles virus first infects only the respiratory tract, then spreads throughout the body. Request Brochure of Report - Measles is one of the leading causes of death among children. According to the World Health Organization (in 1980), measles caused an estimated 2.6 million deaths each year. In 2015, approximately 134200 people died globally due to measles. MMR vaccines (combination of measles, mumps, and rubella vaccine) is given at the time of birth to prevent measles. It is an immunization vaccine and combination of live attenuated viruses of three diseases. In 2015, about 85% of world’s children received one dose of measles vaccine by birthday through routine health services. The Centers for Disease Control and Prevention (CDC) recommended two doses of measles vaccine. One dose of measles vaccine is 93% effective, while two doses of vaccine is 97% effective in preventing measles. The first dose of measles vaccine is recommended at 12 months through 15 months of age, and the second dose at 4 years through 6 years. One dose of vaccination is recommended to adults who did not get vaccinated in childhood. Request for Analysis of COVID-19 Impact on Measles Vaccine Market – The measles vaccine market has been segmented based on product, application, end-user, and region. In terms of product, the market has been categorized into two types: mumps measles rubella vaccine, live (MMR-II) and mumps measles rubella and varicella virus vaccine (Proquad). MMR II (measles, mumps, and rubella virus vaccine live) is a live virus vaccine for vaccination against measles (rubeola), mumps, and rubella (German measles). MMR II is a sterile lyophilized preparation of live virus vaccine containing measles virus, mumps virus, and rubella virus. Proquad is the sterile lyophilized combination of live virus vaccine containing measles, mumps, rubella and varicella virus. Pre book Measles Vaccine Market Report at Based on application, the global measles vaccine market has been divided into pediatric vaccines and adult vaccines. Pediatric vaccines are given in two doses. First at the age of 15 months and second is before the age of six. Pediatric vaccines are more effective than adult vaccines. Adult vaccine is only single dose vaccine. According to CDC, adults born in 1957 or later who have not been vaccinated or have not had measles are recommended one dose of measles vaccine. The pediatric vaccines segment is estimated to account for major share of the global measles vaccine market. In terms end-user, the global measles vaccine market has been segmented into hospitals, clinics, and vaccination centers. Measles vaccines are cost effective and easily available. Top of Form Ask for Discount : Geographically, the global measles vaccine market has been segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to hold high market share of the global measles vaccine market owing to high awareness about the disease and vaccination in the region. Asia Pacific is expected to expand at a high CAGR during the forecast period driven by government initiatives for immunization against measles. Latin America and Middle East & Africa are expected to show significant growth during the forecast period. Growth in the regions is driven by low cost of vaccination. The cost of measles vaccination is less than US$ 1 in these regions. Key players in the global measles vaccine market are MedImmune, Johnson & Johnson Private Limited, Merck & Co., Inc., Sanofi, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Astellas Pharma India Private Limited, CSL Limited, Emergent BioSolutions Inc., and GlaxoSmithKline plc, among others. About Us Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision. Contact Mr. Rohit Bhisey Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website:

An interesting new detail to the Merck whistleblower case about its measles, mumps and rubella vaccine: The scientists that accused Merck for falsifying its measles vaccine data were threatened with jail time, Natural News reports. It’s convenient timing for this to come up, given that anti-vaccer drama is reaching a fever pitch with the recent measles outbreaks. The lawsuit dates to 2010 – why is this being pointed out now? Still, the claims were quite unsettling… In 2010, two virologists – Stephen Krahling and Joan Wlochowski – accused the pharma giant in 2010 of faking the efficacy of its measles vaccine. Merck infused a blood sample with animal antibodies to make it look like the vaccine had elicited increased antibody production, the scientists claimed. This is because, according to the lawsuit, Merck would lose its exclusive license to manufacture the vaccine if it didn’t show 95 percent efficacy. So the whistleblowers claimed that Merck juiced the numbers to keep vaccine sales up. As BioSpace points out, a number of Merck execs knew that data was being falsified – particularly Krahling’s HR representative, Bob Suter, along with several other scientists. The full lawsuit, found here, says: Krahling told Suter that he was going to report the activity to the FDA. Suter told him he would go to jail if he contacted the FDA and offered to set up a private meeting with Emini [then company VP of the Vaccine Research Division] where Krahling could discuss his concerns. This is particularly interesting as Merck has an exclusive license with the U.S. government to produce this measles vaccine. The company brings in $1 billion in revenues yearly on childhood vaccine sales. The lawsuit points out that the FDA requires such a high efficacy rate to promote herd immunity. As the single larger purchaser of childhood vaccines (accounting for more than 50 percent of all vaccine purchases), the United States is by far the largest financial victim of Merck’s fraud. But the ultimate victims here are the millions of children who every year are being injected with a mumps vaccine that is not providing them with an adequate level of protection. And while this is a disease that, according to the Centers for Disease Control, was supposed to be eradicated by now, the failure in Merck’s vaccine has allowed this disease to linger with significant outbreaks continuing to occur. This could prove unfortunate ammo for the anti-vaccer movement. Playing devil’s advocate here, I’m thinking – what if it’s not just flagging immunization rates leading to the increase of once-quashed disease? What if our vaccinations aren’t as effective as they claim to be? It’s an important point to consider. Forbes wrote in 2012: If the accusations are true — thus far Merck has denied wrongdoing — the case would lend credence to the perception held by many that pharmaceutical companies are more interested in pursuing profits and preserving their market share than in protecting consumers’ health.